192 related articles for article (PubMed ID: 4762437)
21. Synthesis and evaluation of antitumor activity of 1-[N, N-bis(2-chloroethyl) sulfamoylphenyl]-3,3-dialkyltriazenes.
Lalezari I; Afghahi F
J Pharm Sci; 1975 Apr; 64(4):698-9. PubMed ID: 1142087
[TBL] [Abstract][Full Text] [Related]
22. The physiological disposition of the carcinostatic imidazole-4 (or 5)-carboxamide, 5(or 4)-[3,3-bis(2-chloroethyl)-1-triazeno] (NSC 82196) (imidazole mustard) in mice and dogs.
Vogel CL; Denham C; Waalkes TP; DeVita VT
Cancer Res; 1970 Jun; 30(6):1651-7. PubMed ID: 5457935
[No Abstract] [Full Text] [Related]
23. Quantitative structure-activity relationships of antineoplastic drugs: nitrosoureas and triazenoimidazoles.
Hansch C; Smith N; Engle R; Wood H
Cancer Chemother Rep; 1972 Aug; 56(4):443-56. PubMed ID: 5081587
[No Abstract] [Full Text] [Related]
24. Intra-arterial infusion therapy with 5-(3,3-dimethyl-1-triazeno) imidazole-4-carboxamide (NSC 45388) for malignant melanoma.
Einhorn LH; McBride CM; Luce JK; Caoili E; Gottlieb JA
Cancer; 1973 Oct; 32(4):749-55. PubMed ID: 4751911
[No Abstract] [Full Text] [Related]
25. Comparison of current alkylating agents with a homo-aza-steroidal ester for antineoplastic activity.
Catsoulacos P; Papageorgiou A; Margarity E; Mourelatos D; Mioglou E
Oncology; 1994; 51(1):74-8. PubMed ID: 8265107
[TBL] [Abstract][Full Text] [Related]
26. Potential antitumor agents: steroidal amidoesters with an alkylating moiety.
Papageorgiou A; Boutis L; Nicolaropoulos S; Catsoulacos P
Oncology; 1987; 44(2):128-32. PubMed ID: 3574853
[TBL] [Abstract][Full Text] [Related]
27. Clinical experience with 5-(3,3-bis(2-chloroethyl)-1-triazeno)imidazole-4-carboxamide (NSC-82196) in the treatment of metastatic malignant melanoma.
Falkson G; Van der Merwe AM; Falkson HC
Cancer Chemother Rep; 1972 Oct; 56(5):671-7. PubMed ID: 4569061
[No Abstract] [Full Text] [Related]
28. Chemotherapy of sarcomas with a combination of adriamycin and dimethyl triazeno imidazole carboxamide.
Gottlieb JA; Baker LH; Quagliana JM; Luce JK; Whitecar JP; Sinkovics JG; Rivkin SE; Brownlee R; Frei E
Cancer; 1972 Dec; 30(6):1632-8. PubMed ID: 4663966
[No Abstract] [Full Text] [Related]
29. Kinetics of the effect of 5(or 4)-(3,3-dimethyl-1-triazeno)-imidazole-4 (or 5) -carboxamide (NSC-45388) and 5(or 4)-[3,3-bis(2-chloroethyl)-1-triazeno]imidazole-4(or 5)-carboxamide (NSC-82196) on the reproductive integrity of cultured leukemia L1210 cells.
Wilkoff LJ; Dulmadge EA; Dixon GJ
Cancer Chemother Rep; 1968 Dec; 52(7):725-32. PubMed ID: 5754670
[No Abstract] [Full Text] [Related]
30. Chemoimmunotherapy of disseminated malignant melanoma with dimethyl triazeno imidazole carboxamide and bacillus calmette--guérin.
Gutterman JU; Mavligit G; Gottlieb JA; Burgess MA; McBride CE; Einhorn L; Freireich EJ; Hersh EM
N Engl J Med; 1974 Sep; 291(12):592-7. PubMed ID: 4851001
[No Abstract] [Full Text] [Related]
31. 5(or 4)-[3,3-bis(2-chloroethyl)-1-triazeno]imidazole-4(or 5)-carboxamide (NSC-82196)--clinical brochure.
Carter SK; Newman JW
Cancer Chemother Rep 3; 1968 Dec; 1(1):63-80. PubMed ID: 4989815
[No Abstract] [Full Text] [Related]
32. Results of a randomized study comparing DTIC with TIC mustard in malignant melanoma.
Costanza ME; Nathanson L; Costello WG; Wolter J; Brunk SF; Colsky J; Hall T; Oberfield RA; Regelson W
Cancer; 1976 Apr; 37(4):1654-9. PubMed ID: 769936
[TBL] [Abstract][Full Text] [Related]
33. Chemotherapeutic, carcinogenic, and cell-regulatory effects of triazenes.
Schmid FA; Hutchison DJ
Cancer Res; 1974 Jul; 34(7):1671-5. PubMed ID: 4833916
[No Abstract] [Full Text] [Related]
34. [Polychemotherapy with 5-(3,3 dimethyl-1-triazeno)imidazole-4-carboxamide (DTIC; NSC-45388), 1,3-bis (2-chloroethyl)-1-nitrosourea (BCNU, NSC-409962) and vincristine (NSC-67574) in the metastatic phase of melanoma].
Beretta G; Bajetta E; Bonadonna G; Tancini G; Orefice S; Veronesi U
Tumori; 1973; 59(3):239-48. PubMed ID: 4729646
[No Abstract] [Full Text] [Related]
35. Antigenic changes of L1210 leukemia in mice treated with 5-(3,3-dimethyl-1-triazeno)imidazole-4-carboxamide.
Bonmassar E; Bonmassar A; Vadlamudi S; Goldin A
Cancer Res; 1972 Jul; 32(7):1446-50. PubMed ID: 4402275
[No Abstract] [Full Text] [Related]
36. Enhanced response of leukemia (L1210) mice to combination chemotherapy with 5-(3,3-dimethyl-1-triazeno) imidazole-4-carboxamide (NSC-45388) and 5-fluorouracil (NSC-19893).
Kline I; Woodman RJ; Gang M; Waravdekar VS; Goldin A; Venditti JM
Cancer; 1971 Jun; 27(6):1363-8. PubMed ID: 5088212
[No Abstract] [Full Text] [Related]
37. Antitumor activity of tetraacetylglucosamine mustard.
Wampler GL; Nassiri SK; Hsiao YY; Bardos TJ; Regelson W
Cancer Res; 1975 Aug; 35(8):1903-6. PubMed ID: 1149014
[TBL] [Abstract][Full Text] [Related]
38. Effect of a delta 5-homo-aza-steroidal ester in P388 and L1210 murine leukemias.
Catsoulacos P; Camoutsis C; Wampler GL
Oncology; 1982; 39(1):59-60. PubMed ID: 7058047
[TBL] [Abstract][Full Text] [Related]
39. Potentially useful combinations of chemotherapy detected in mouse tumor systems.
Kline I
Cancer Chemother Rep 2; 1974 Mar; 4(1):33-43. PubMed ID: 4133187
[No Abstract] [Full Text] [Related]
40. Antitumor effect of pyridine N-oxides having 1-(2-chloroethyl)-1-nitrosoureidoalkyl and 1-methyl-1-nitrosoureidoalkyl groups.
Miyahara M; Kamiya S; Maekawa A; Odashima S
Gan; 1979 Dec; 70(6):731-6. PubMed ID: 535684
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
